Charles River Laboratories International, Inc. reported its financial results for the third quarter of fiscal 2025, revealing a slight decline in revenue and net income compared to the same period last year. For the three months ended September 27, 2025, the company generated total revenue of $1.004 billion, a decrease of 0.5% from $1.010 billion in the prior year. The nine-month revenue also fell by 0.9% to $3.021 billion from $3.047 billion. The decline was primarily attributed to reduced demand in the Discovery and Safety Assessment (DSA) and Manufacturing segments, which faced cautious client spending, partially offset by increased revenue in the Research Models and Services (RMS) segment.
In terms of profitability, net income attributable to Charles River Laboratories decreased to $54.4 million, or $1.11 per diluted share, for the third quarter, down from $69.7 million, or $1.33 per diluted share, in the same quarter of 2024. For the nine-month period, net income fell to $132.2 million from $236.7 million in the previous year. The decrease in net income was influenced by higher losses and impairments on venture capital and strategic equity investments, alongside increased restructuring costs and legal expenses.
Operationally, the company reported a total of 49.2 million shares outstanding as of September 27, 2025. The RMS segment saw a revenue increase of 7.9% to $213.5 million, driven by strong performance in large research model products, particularly from Noveprim. Conversely, the DSA segment's revenue decreased by 2.3% to $600.7 million, reflecting lower volumes due to client budget reassessments. The Manufacturing segment also experienced a revenue decline of 3.1% to $190.7 million, primarily due to decreased demand for contract development and manufacturing services.
Looking ahead, Charles River Laboratories is implementing a comprehensive strategic review aimed at enhancing its scientific portfolio and operational efficiency. The company anticipates annual cost savings of approximately $225 million, with $175 million expected to impact fiscal 2025. Additionally, the company is navigating ongoing investigations related to its non-human primate supply chain and has expressed confidence in its ability to manage these challenges while continuing to focus on strategic acquisitions and partnerships to drive growth.
About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Charles River Laboratories International, Inc. is a global provider of non-clinical drug development services, offering research models, discovery and safety assessment, and manufacturing solutions. Serving pharmaceutical, biotechnology, chemical, and academic clients worldwide, it supports early-stage drug discovery through regulatory safety testing and biologics manufacturing. The company’s integrated portfolio, scientific expertise, and global infrastructure enable efficient, cost-effective outsourcing to accelerate therapeutic innovation and reduce time to market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.